CE: Optimizing pharmacists’ care of people with type 2 diabetes; focus on GLP-1 RA therapy

This program seeks to provide pharmacists with an evidence-based, stepwise approach to supporting people with type 2 diabetes, with a focus on optimizing glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in a pharmacy practice.

This continuing education course for pharmacists is approved by CCCEP for 1.25 credits.  Course # 1329-2023-3623-I-P.

Supported by an unrestricted educational grant from Novo Nordisk Canada.

Learning objectives

1. Identify people with type 2 diabetes who could benefit from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, according to the Diabetes Canada Clinical Practice Guidelines (CPGs), for:

• cardiovascular risk reduction
• obtaining glycemic target(s) while minimizing hypoglycemia
• weight management support

2. Discuss practical patient-management considerations for GLP-1 RAs, such as dosing, side effects, use in special populations, and the impact on other comorbidities

3. Formulate a management plan and succinctly communicate this plan with the person’s diabetes healthcare team

Course author: Susie Jin, RPh, CDE CRE

This continuing education is free for members of CanadianHealthcareNetwork.ca. Log in and click here to take the course: